Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

However, it isn't there yet, and in the meantime, it is facing problems leading to its share price falling. Recursion Pharmaceuticals recently released its first-quarter results, during which it ...